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Pyrrolizine-5-carboxamides: Exploring the impact of various 
substituents on anti-inflammatory and anticancer activities
Towards optimization of the pyrrolizine-5-carboxamide scaffold, 
a novel series of six derivatives (4a-c and 5a-c) was prepared and 
evaluated for their anti-inflammatory, analgesic and anticancer 
activities. The (EZ)-7-cyano-6-((4-hydroxybenzylidene)amino)-
N-(p-tolyl)-2,3-dihydro-1H-pyrrolizine-5-carboxamide (4b) and 
(EZ)-6-((4-chlorobenzylidene)-amino)-7-cyano-N-(p-tolyl)-
2,3-dihydro-1H-pyrrolizine-5-carboxamide (5b) bearing the 
electron donating methyl group showed the highest anti-inflam-
matory activity while (EZ)-6-((4-chlorobenzylidene)amino)-
7-cyano-N-phenyl-2,3-dihydro-1H-pyrrolizine-5-carboxamide 
(5a) was the most active analgesic agent. Cytotoxicity of the new 
compounds was evaluated against the MCF-7, A2780 and HT29 
cancer cell lines using the MTT assay. Compounds 4b and 5b 
displayed high anticancer activity with IC50 in the range of 0.30–
0.92 µmol L–1 against the three cell lines, while compound (EZ)-
N-(4-chlorophenyl)-7-cyano-6-((4-hydroxybenzylidene)-
amino)-2,3-dihydro-1H-pyrrolizine-5-carboxamide (4c) was the 
most active against MCF-7 cells (IC50 = 0.08 µmol L–1). Both the 
anti-inflammatory and anticancer activities of the new com-
pounds were dependent on the type of substituent on the phenyl 
rings. Substituents with opposite electronic effects on the two 
phenyl rings are preferable for high cytotoxicity against the 
MCF-7 and A2780 cells. COX inhibition was suggested as the 
molecular mechanism of the anti-inflammatory activity of the 
new compounds while no clear relationship could be observed 
between COX inhibition and anticancer activity. Compound 5b, 
the most active against the three cell lines, induced dose-depen-
dent early apoptosis with 0.1–0.2 % necrosis in MCF-7 cells. New 
compounds showed promising drug-likeness scores while the 
docking study revealed high binding affinity to COX-2. Taken 
together, this study highlighted the significant impact of the 
substituents on the anti-inflammatory and anticancer activity of 
pyrrolizine-5-carboxamides, which could help in further opti-
mization to discover good leads for the treatment of cancer and 
inflammation.
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Cancer and inflammation are closely linked biological processes where many anti-
inflammatory agents displaying anticancer activity have provided evidence for this tight 
correlation (1–4). The use of NSAIDs in prevention and treatment of cancer has been discussed 
in several reports. NSAIDs can restore normal apoptosis and inhibit angiogenesis in cancer 
cells (2). Moreover, the COX-2 enzyme plays an important role in cellular proliferation and 
apoptosis (4). The upregulation of COX-2 in benign and malignant cancers provided evidence 
for this role (5). In addition, several COX-2 inhibitors displayed potent anticancer activity 
mediated by the induction of apoptosis (6, 7).
Recently, several reports have focused on the anti-inflammatory and anticancer acti-
vities of the pyrrolizine derivatives (8–10). Licofelone (Fig. 1) is one of the derivatives that 
underwent a phase III clinical trial as an anti-inflammatory drug (11). Licofelone also dis-
played potent anticancer activity with an IC50 value of 5.5 µmol L–1 against the human breast 
MCF-7 cell line (12). Although licofelone acts as a dual COX/5-LOX inhibitor, Tavolari et al. 
(13, 14) have provided evidence that it induces apoptosis through the mitochondrial path-
way instead of COX/5-LOX inhibition.
MR22388 is another pyrrolizine derivative that showed potent antiproliferative activity 
against the leukemia L1210 cell line with the IC50 value of 15 nmol L–1 (Fig. 1). The anti-
cancer activity of MR22388 was mediated by the induction of apoptosis, inhibition of 
 tubulin polymerization and inhibition of several kinases (15–17). Moreover, we have 
 reported several pyrrolizine-5-carboxamide derivatives with potent anticancer activity 
against the MCF-7 and A549 cancer cell lines (9, 18). Anticancer activities of these pyrro-
lizines were associated with activation of caspase 3/7 enzymes, inhibition of COXs and 
 induction of apoptosis (9, 18).
In this study, scaffold A was designed by bearing two phenyl rings (A and B) attached 
to the pyrrolizine nucleus via two atom spacers (Fig. 1). To evaluate the impact of elec-
tronic effects of the substituents on the two phenyl rings on the anti-inflammatory, anal-
Fig. 1. Pyrrolizine-based anticancer agents and rational design of scaffold A.
253
A. M. Gouda et al.: Pyrrolizine-5-carboxamides: Exploring the impact of various substituents on anti-inflammatory and anticancer 
activities, Acta Pharm. 68 (2018) 251–273.
 
gesic and anticancer activities of the new pyrrolizines, different types of substituents, 
 including electron-donating groups (CH3 and OH) and electron-withdrawing group (Cl), 
were used in the new compounds.
EXPERIMENTAL
Chemicals and instruments
All the chemical reagents and solvents used were purchased from Sigma-Aldrich 
(USA). Solvents were dried according to the literature when necessary. Purity of the new 
compounds was checked with TLC. Melting points are uncorrected and were determined 
with an IA 9100MK-Digital melting point apparatus (Cole-Parmer, USA). Infrared spectra 
(IR) were recorded using a BRUKER TENSOR 37 spectrophotometer (Bruker, USA) from 
KBr discs. The proton magnetic spectra were recorded on a BRUKER AVANCE III at 500 
MHz (Bruker) in CDCl3 and J constants were given in Hz. The 13C NMR and DEPT135 
(distortionless enhancement by polarization transfer) spectra of the new compounds in 
CDCl3 were done on the BRUKER AVANCE III (Bruker) at 125 MHz. Mass spectra were 
recorded using GCMS on a Shimadzu Qp-2010 Plus mass spectrometer (Shimadzu, Ja-
pan) at 70 eV (EI).
Syntheses
2-Pyrrolidin-2-ylidene-malononitrile (1). – Synthesis of 2-pyrrolidin-2-ylidene-malononi-
trile (1) was achieved according to previous reports (19). To a solution of 2-pyrrolidinone 
(2.5 g, 29.4 mmol) in dry benzene (30 mL), dimethyl sulfate (CH3)2SO4 (3.7 g, 29.4 mmol) 
was added under stirring. The reaction mixture was refluxed for 3 hours and then al-
lowed to cool to room temperature. The solution was cooled in an ice-bath and ren-
dered alkaline by dropwise addition of sodium hydroxide (15 mol L–1, 1.5 mL). The 
temperature was kept below 5 °C during the addition of sodium hydroxide. The or-
ganic phase was separated, dried over anhydrous sodium sulfate and filtered. Malono-
nitrile (1.25 g, 19.1 mmol) was added to the benzene solution at room temperature. The 
produced solution was then stirred, whereby white crystals were formed on scratching 
the wall of the beaker. The crystals were collected, dried to give 5.2 g and recrystallized 
from aqueous ethanol.
2-Chloro-1N-[4-(un)substituted-phenyl)-acetamide (2a-c). – Synthesis of acetanilides 2a-c 
was achieved according to a previous report (20) with some modifications. The appro-
priate aniline (27 mmol) was dissolved in a small amount of glacial acetic acid. Chloroacetyl 
chloride (4.55 g, 40.5 mmol) was added dropwise to the solution under continuous stirring 
and cooling. After addition of chloroacetyl chloride was completed, a saturated solution of 
sodium acetate (1.5 mL) was added dropwise under stirring. The solution was kept cool 
during the addition of chloroacetyl chloride by using an ice-cooled water-bath. The white 
precipitate formed was collected on a Büchner funnel, washed with water 2 times (2 × 30 mL) 
and recrystallized from aqueous ethanol. The following compounds were prepared: 
2-chloro-N-phenylacetamide (2a), 2-chloro-N-(p-tolyl)acetamide (2b) and 2-chloro-N-(4-
chlorophenyl)acetamide (2c).
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6-Amino-7-cyano-N-[4-(un)substituted-phenyl]-2,3-dihydro-1H-pyrrolizine-5-carboxamide 
(3a-c). – Synthesis of pyrrolizine-5-carboxamides 3a-c was achieved according to a pre-
vious report (21). Appropriate acetanilides 2a-c (7.5 mmol) were refluxed for 24 h with 
an equimolar ratio of 2-pyrrolidin-2-ylidene-malononitrile (1) in dry acetone in the pres-
ence of a catalytic amount of anhydrous potassium carbonate (0.5 g, 3.75 mmol). The 
mixture was filtered while hot, the content of the flask was washed 2 times with acetone 
(2 × 15 mL), left to cool and yellowish white crystals were separated. The following 
compounds were prepared: 6-amino-7-cyano-N-phenyl-2,3-dihydro-1H-pyrrolizine-
5-carboxamide (3a), 6-amino-7-cyano-N-(p-tolyl)-2,3-dihydro-1H-pyrrolizine-5-car-
boxamide (3b) and 6-amino-N-(4-chlorophenyl)-7-cyano-2,3-dihydro-1H-pyrroli-
zine-5-carboxamide (3c).
(EZ)-7-cyano-6-((4-hydroxy/chlorobenzylidene)amino)-N-(un)substitutedphenyl-2,3-di-
hydro-1H-pyrrolizine-5-carboxamide (4a-c and 5a-c). General procedures. – A mixture of the ap-
propriate pyrrolizine-5-carboxamides 3a-c (2 mmol) and appropriate aldehyde (2.2 mmol) in 
absolute ethanol (30 mL) in the presence of glacial acetic acid (0.5 ml) was refluxed for 6 hours. 








Elemental analysis (%) MS (EI) 
Calcd. Found








m/z (%) 373 (M++3, 22), 372 (M++2, 
5), 371 (M++1, 20), 370 (M+, 100), 369 
(M+-1, 75), 298 (11), 77 (1)








m/z (%) 388 (M++4, 3), 370 (79), 280 
(2), 279 (19), 278 (100), 277 (32), 266 
(40), 250 (25), 174 (18), 92 (19), 77 
(17)








m/z (%) 407 (M++3, 2), 406 (M++2, 8), 
405 (M++1, 7), 404 (M+, 27), 403 
(M+-1, 7), 370 (100), 278 (4)








m/z (%) 391 (M++3, 3), 390 (M++2, 
20), 389 (M++1, 25), 388 (M+, 69), 370 
(5), 296 (100), 277 (11), 77 (1)








m/z (%) 405 (M++3, 3), 404 (M++2, 9), 
403 (M++1, 7), 402 (M+, 26), 401 
(M+-1, 2), (370 (9), 296 (100), 268 (3), 
77 (8)








m/z (%) 425 (M++3, 8), 424 (M++2, 
20), 423 (M++1, 6), 422 (M+, 28), 383 
(27), 372 (37), 354 (21), 339 (16), 311 
(22), 296 (100), 280 (19), 155 (2), 113 
(3), 77 (2)
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The reaction mixture was then concentrated and set aside to cool. The yellow crystals formed 
were collected and recrystallized from chloroform-acetone (1:1). The following compounds 
were prepared: (EZ)-7-cyano-6-((4-hydroxybenzylidene)amino)-N-phenyl-2,3-dihydro-1H-





pyrrolizine-5-carboxamide (5b) and (EZ)-6-((4-chlorobenzylidene)amino)-N-(4-chloro-
phenyl)-7-cyano-2,3-dihydro-1H-pyrrolizine-5-carbox-amide (5c).
Physicochemical properties and spectral data of the synthesized compounds are pre-
sented in Tables I and II.
Animals
The anti-inflammatory testing of the new compounds 4a-c and 5a-c was performed on 
adult albino rats (both sexes) weighing 100–140 g, while the analgesic activity was tested on 
albino mice of either sex (18–22 g). The animals were acquired from the animal house of 
King Abdul-Aziz University Medical Research Centre, Jeddah (Kingdom of Saudi Arabia). 
The animals were housed in polypropylene cages bedded with wooden husk. The animals 
were kept with food and tap water ad libitum and under a 12 h light/dark cycle).
Animals were divided into 8 groups of six animals each. Rats were hydrated orally 
with 3 mL water. Animals were kept in the lab for one week before starting the tests so as to 
adapt to lab conditions.
The animal ethical clearance was obtained from the Ethical Committee of the College of 
Pharmacy, Umm Al-Qura University, Makkah, KSA.
Pharmacological screening
Anti-inflammatory activity. – Carrageenan induced rat paw edema method was used 
for the anti-inflammatory activity evaluation according to a previous report (22). The 
control group was given saline solution containing a few drops of carboxy methyl cellulose 
(CMC) (group I). Ibuprofen (100 mg kg–1, 0.48 mmol kg–1 bm) prepared in distilled water 
containing a few drops of CMC was given to group II. Tested compounds 4a-c and 5a-c (0.48 
mmol kg–1 bm) suspended in distilled water containing a few drops of CMC were given to 
groups III-VIII.
Experimental procedures were performed following our previous report (10). In-
duction of inflammation was performed by a subcutaneous (s.c.) injection of 50 µL of 0.5 % 
carrageenan-sodium gel (Sigma-Aldrich, USA) into the sub-plantar region of the right 
hind paw. The dorsoventral diameter (thickness) of the right and left hind paws of each rat 
was measured using digital calipers with 0.01 mm accuracy (Cole-Parmer, USA). Edema 
thickness was measured 2 and 3 h after induction of inflammation. Results are presented 
in Table III.
In vivo analgesic activity. – Analgesic activity of the new compounds 4a-c and 5a-c was 
evaluated using the hot-plate test according to a previous report (23). The standard drug, 
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ibuprofen (100 mg kg–1 bm), and the test compounds (both 0.48 mmol kg–1 bm) were given 
orally. Experimental procedures were performed following a previous report (10). Analgesic 
effect of the tested compounds was calculated as the percentage of the maximal protective 
effect. Results are presented in Table III.
In vitro COX-1/2 inhibition assay. – All new compounds (4a-c and 5a-c) were tested for 
their inhibitory activity against both COX-1 (ovine) and COX-2 (human recombinant) en-
zymes. A COX inhibitor screening assay kit (Cayman Chemicals, USA) was used in the 
assay. The assay was done following the manufacturer’s instructions and as mentioned 
before (24). The results were presented as % inhibition at a 10 µmol L–1 concentration of the 
new compounds. Indomethacin and celecoxib were used as reference drugs. Results are 
presented in Table IV.
Growth inhibition
Cell cultures. – Human breast MCF-7, ovarian A2780 and colon HT29 cancer cell lines 
were obtained from the American Type Culture Collection (Manassas, VA, USA). All cells 
were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10 % fetal 
bovine serum (FBS, Gibco, USA) in a humidified incubator containing 5 % CO2 at 37 ° C.
Cytotoxic activity. – The MTT (3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium 
bromide, Merck, Germany) assay was used to investigate the anticancer activity of the new 
compounds following a previous report (25). Cells were seeded for 24 h (3 × 103) in 96-well 
flat-bottomed plates. Seeded cells were then treated with the test compounds or lapatinib 
(n = 6). DMSO vehicle (0.1 %, V/V) was used as a negative control. Cells were treated with 
the tested compounds in final drug concentrations of 0.00, 0.05, 0.50, 5.00, 25.00 and 50.00 
µmol L–1. After 72 h, MTT was added for 3 h at 37 °C. Reduced MTT was dissolved in DMSO 
(100 µL per well). Absorbance was measured using a microplate reader at 570 nm and the 












a Inhibition of COX-1 (ovine) and COX-2 (human recombinant) at 10 µmol L–1.
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readings were corrected by subtracting the negative control readings. Experiments were 
repeated three times independently. Results are represented in Table V.
Annexin V PI/FITC apoptosis assay. – Annexin V Propidium iodide/fluorescein isothio-
cyanate (PI/FITC) was used to evaluate the ability of compound 5b to induce apoptotic 
changes in MCF-7 cells. Experimental procedures were done as previously reported (26). 
Three experiments were performed independently. Results are presented in Fig. 5.
Statistics
Anti-inflammatory and analgesic data were analyzed by One-way ANOVA followed 
by the Student-Newman-Keuls multiple comparison test.
Computational studies
Drug-likeness study. – Although a huge number of anticancer agents with potent activity 
in vitro have been reported in the last three decades, only a few have passed to clinical trials. 
This problem is mainly due to the ADME (absorption, distribution, metabolism and 
elimination) problems. In this work, the drug-likeness related parameters were deter-








R2 = OH, Cl





MCF-7 A2780 HT29 Average value
4a H OH 0.31 ± 0.05 2.56 ± 0.29 0.96 ± 0.13 1.28
4b CH3 OH 0.76 ± 0.60 0.92 ± 0.05 0.30 ± 0.16 0.67
4c Cl OH 0.08 ± 0.01 0.52 ± 0.02 3.79 ± 1.39 1.46
5a H Cl 1.12 ± 0.66 0.78 ± 0.30 0.37 ± 0.05 0.76
5b CH3 Cl 0.33 ± 0.12 0.44 ± 0.01 0.41 ± 0.02 0.40
5c Cl Cl 1.77 ± 0.29 3.92 ± 0.07 0.72 ± 0.07 2.14
Lapatinib – – 6.80 ± 1.20 10.40  ± 0.80 12.67 ± 1.33 9.96
Results are mean ± SD (n = 6 repetitive measurements, 3 independent experiments), after 72-h treatment with test 
compounds, lapatinib or 0.1 % DMSO (control).
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mined for the new compounds according to Lipinski’s “rule of five” (27). The predicted 
values of the physicochemical properties of the new compounds were calculated using the 
SwissADME webserver developed by the Swiss Institute of Bioinformatics (SIB, Switzer-
land, http://www.swissadme.ch/) (28). Results are represented in Table VI.
The molecular mass (MW), molar refractivity (MR), lipophilicity (MlogP), number of 
hydrogen bond donors (HD), number of hydrogen bond acceptors (HA), Lipinski violations 
(27), number of rotatable bonds and topological polar surface area (TPSA) of the new com-
pounds 4a-c and 5a-c and of licofelone were calculated. Chemical structures of the new 
compounds were sketched using the Marvin JS sketcher (version 16.4.18, 2016, www.che-
maxon.com), converted to smiles by the JChem web service and processed through a series 
of actions when the calculation started upon clicking “RUN”. The results were obtained as 
an Excel output file. The molecular volume and drug-likeness score (DLS) were calculated 
using the Molsoft webserver developed by Molsoft LLC (USA, http://molsoft.com/mprop/). 
The results are presented in Table VI.
Molecular docking study. – Docking study of all the new compounds was performed on 
COX enzymes. AutoDock 4.2 was used in the study and a Discovery Studio Visualizer 
(v16.1.0.15350) was used in visualization of the docking poses. Crystal structures of COX-1 
(pdb code: 1EQG) (29) and COX-2 (pdb code: 1CX2) (30) were obtained from the protein 
data bank (http://www.rcsb.org/pdb). The protein structure was prepared by deleting water 
molecules and native ligands. Validation of the docking studies was done by re-docking 
the native ligands with their corresponding proteins. Binding modes and interactions of 
the native ligands with the key amino acids in the active site were identified and compared 
with the reported data.
Table VI. Molecular properties related to drug-likeness of compounds 4a-c, 5a-c and licofelone
Compd. Mr MVa MR TPSA MlogP RBs HA HD LVs DLSa
4a 370.4 382.82 108 90.41 1.6 5 4 2 0 0.55
4b 384.43 403.76 112.97 90.41 1.81 5 4 2 0 0.57
4c 404.85 400.01 113.01 90.41 2.08 5 4 2 0 1.00
5a 388.85 389.46 110.99 70.18 2.63 5 3 1 0 0.76
5b 402.88 410.40 115.95 70.18 2.84 5 3 1 0 0.81
5c 423.29 406.66 116 70.18 3.11 5 3 1 0 0.84
Licofelone 379.88 383.88 110.13 42.23 4.26 4 2 1 1b 0.58
DLS – drug-likeness score, HA – hydrogen bond acceptors, HD – hydrogen bond donors, LVs – Lipinski violation, Mr 
– molecular mass, MV – molecular volume, TPSA – topological polar surface area, MlogP – Moriguchi’s log P, RBs 
– rotatable bonds
a Parameters calculated using Molsoft: http://molsoft.com/mprop/; other parameters calculated using SwissADME 
(http://www.swissadme.ch/).
b There is one violation (MlogP > 4.15).
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Preparation of the protein (COX-1, COX-2) pdbqt files. – Crystal structures of the proteins 
co-crystallized with the native ligands were obtained from the Protein Data Bank (http://
www.rcsb.org/pdb) as pdb files. COX-1 (pdb code: 1EQG) and COX-2 (pdb code: 1CX2) were 
obtained in X-ray resolution of 2.61 and 3.0 Å, resp. (29, 30). A discovery studio visualizer 
(DSV, v16.1.0.15350) was used to handle the protein structures. During preparation of the 
proteins, water molecules and bound ligands were removed to avoid interference with the 
study. The pdb files of the test compounds were prepared using Chem3D Ultra 8.0 followed 
by MOPAC energy minimization. The docking study was performed using AutoDock 4.2.
Preparation of ligand files. – Chemical structures of the new compounds were sketched 
using the ChemDraw Ultra 8.0 software. Chem3D Ultra 8.0 was used in the preparation of 
the ligand in the pdb format. Energies of the ligands were minimized using MOPAC with 
100 iterations. The AutoDock Tool 1.5.6 was used to read the pdb files, add the hydrogens, 
compute Gasteiger charges, and to convert the pdb into the pdbqt format for the docking 
study. The docking scenario was done using flexible ligands while the rotatable bonds in 
the ligands were assigned using AutoDock tools (ADT) 1.5.6.
Preparation of affinity maps and running AutoGrid. – Preparation of the Grid parameter 
files by AutoDock was done using AutoGrid, which generated a map for each type of atom 
in the docking area. The 3D grids with the final size of 60 × 60 × 60 Å with 0.375 Å spacing 
were used in the study. The center of the grid for COX-1 was assigned at 26.643, 33.106 and 
200.251 Å, and for COX-2 at 23.947, 21.582 and 15.436 Å.
Preparation of the docking parameter file and running AutoDock. – The protein molecule 
and the ligand were selected to run AutoDock and perform docking calculations. The 
docking parameter file was set to the default values. In this study, we set the proteins as a 
rigid file while ligands were used as flexible molecules. Lamarckian genetic algorithm was 
set as the search parameter. After running AutoDock, the top ten conformations of the 
protein-ligand complex were clustered. Docking poses were scored and ranked in decreas-
ing order of their binding free energy.
Analysis and visualization of the results. – AutoDock 4.2. was used in the analysis of the 
docking results, determination of the binding free energy (∆Gb) and inhibition constants 
(Ki). Binding modes of the ligand and the type of ligand-protein interactions were vitalized 
using a discovery studio visualizer (v16.1.0.15350). The 2D/3D binding mode was visual-
ized showing both hydrogen bonding and hydrophobic interactions. The docking results 
are presented in Table VII and Figs. 6 and 7.
RESULTS AND DISCUSSION
Chemistry
Preparations of 2-pyrrolidin-2-ylidene-malononitrile (1), 2-chloro-1N-[4-(un)substitut-
ed-phenyl)-acetamides (2a-c) and 6-amino-7-cyano-N-[4-(un)substituted-phenyl]-2,3-di-
hydro-1H-pyrrolizine-5-carboxamides (3a-c) outlined in Scheme I were achieved following 
previous reports (19–21).
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Schiff bases 4a-c and 5a-c were obtained by the reaction of compounds 3a-c with a proper 
aldehyde (4-hydroxybenzaldehyde or 4-chlorobenzaldehyde) in ethanol (see Scheme 1). 
Structural characterization of new compounds 4a-c and 5a-c was accomplished using IR, 
1H NMR, 13C NMR and mass spectra, in addition to elemental analyses (Tables I and II).
IR spectra of the new compounds 4a-c and 5a-c revealed absorption bands in the 
range of 3216–3324 cm–1 indicating the NH of the amide groups, absorption bands in the 
range of 2211–2214 cm–1 assigned to the cyano groups and stretching bands in the range of 
1662–1671 cm–1 attributed to the carbonyl groups.
1H NMR spectra of compounds 4a-c revealed three signals in the range of 2.50–4.56 ppm 
attributed to the aliphatic methylene groups of pyrrolizine nucleus. The 1H NMR spectrum 
of compound 4b revealed a singlet signal at 2.42 ppm assigned to the methyl group. A singlet 
signal in the range of 5.49–5.58 ppm was due to the protons of hydroxyl (OH) groups in com-
pounds 4a-c. Aromatic protons of compound 4a appeared as two triplets at 7.10 and 7.38 ppm, 
in addition to three doublets at 6.97, 7.64 and 7.87 ppm, while the aromatic protons in com-
pounds 4b and 4c appeared as four doublets in the range of 6.96–7.87 ppm. Two singlet signals 
were observed in the range of 8.37–10.51 ppm indicating benzylidene and amide protons, 
respectively. Superimposition of aromatic and amide protons in compound 4a and in the in-
termediate compound (6-amino-7-cyano-N-phenyl-2,3-dihydro-1H-pyrrolizine-5-car-
boxamide) showed two new aromatic signals, in addition to a singlet signal of the benzyli-
dene (N=CH) proton (Fig. 2).
The 1H NMR spectrum of compound 5b showed a singlet signal at 2.36 ppm due to the 
methyl group. Moreover, the 1H NMR spectrum of compound 5a revealed three signals in the 
Reagents and reaction conditions: a) (CH3)2SO4, benzene, malononitrile, b) ClCH2COCl, glacial acetic 
acid, CH3COONa, c) K2CO3, acetone, reflux, 24 h, d) appropriate aldehyde (4-hydroxy/4-chloro-benz-




























2a, 3a: R1 = H;
2b, 3b: R1 = CH3;
2c, 3c: R1 = Cl;
4a: R1 = H, R2 = OH;
4b: R1 = CH3, R2 = OH;
4c: R1 = Cl, R2 = OH;
5a: R1 = H, R2 = Cl;
5b: R1 = CH3, R2 = Cl;
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Fig. 3. Superimposition of the aromatic, benzylidene and amidic protons in compound 5a (green) on 
the respective protons of compound 3a (pink).
Fig. 2. Superimposition of the aromatic, benzylidene and amidic protons in compound 4a (green) over 
the corresponding protons of compound 3a (pink).
range of 2.55–4.56 ppm attributed to the methylene groups of the pyrrolidine ring. Aromatic 
protons of compound 5a appeared as two triplets at 7.15 and 7.39 ppm plus three doublets at 
7.53, 7.65 and 7.87 ppm, while the aromatic protons in compounds 5b and 5c appeared as four 
doublets in the range of 7.17–7.88 ppm indicating para-substituted phenyl rings. Two singlet 
signals at 8.91 and 10.47 ppm indicated benzylidene and amide protons, resp.
Superimposition of aromatic and amide protons in compound 5a and the preceding 
compound 3a showed two new aromatic signals, in addition to the benzylidene (N=CH) 
proton (Fig. 3).
On the other hand, the 13C NMR spectra of compounds 4a-c and 5a-c revealed three 
signals in the range of 24.49–50.38 ppm attributed to the three aliphatic carbons of the pyr-
rolizine nucleus, two signals at 21.42 and 20.92 ppm attributed to the methyl (CH3) groups 
in compounds 4b and 5b, resp. In addition, two signals in the range of 157.95–161.95 ppm 
were assigned to the benzylidene (C=NH) and carbonyl carbons in compounds 4a-c and 
5a-c.
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Pharmacological screening
In vivo anti-inflammatory activity. – Results of the anti-inflammatory activity are given 
as changes in edema thickness, inhibition of inflammation and relative potency compared 
to ibuprofen (Table III).
It was noticed that all new compounds showed moderate anti-inflammatory activ-
ity with relative potency in the range of 0.53–0.84 compared to ibuprofen. Ibuprofen 
and the new compounds (4a-c and 5a-c) were significantly different from the control (p = 
0.001). 
Compounds 4a and 5a with the unsubstituted phenyl ring displayed anti-inflamma-
tory activity of 35.6 and 29.7 %, resp. In general, the methyl-substituted analogs (4b and 5b) 
displayed higher anti-inflammatory activity than the other derivatives (Table III).
In vivo analgesic activity. – Results from Table III revealed that all new compounds have 
analgesic activity lower than ibuprofen. Compounds 4a-c with the 4-hydroxy substituent 
were less active than their 4-chloro analogs 5a-c. Compound 5a showed the highest analge-
sic activity after 3 hours (Table III).
In vitro COX-1/2 inhibitory activity. – New compounds 4a-c and 5a-c displayed inhibi-
tory activity for COX-1/2 enzymes with inhibition in the range of 18–32 % for COX-1 and 
41–48 % for COX-2 at 10 µmol L–1. Compound 4c bearing 4-hydroxyphenyl was the most 
active COX-2 inhibitor while compound 5a was the most active inhibitor of COX-1. All new 
compounds displayed inhibitory activity against COX-1 and COX-2 enzymes with inhibi-
tion lower than that of both the non-selective COX inhibitor (indomethacin) and the selec-
tive COX-2 inhibitor (celecoxib). All the inhibitions by the tested compounds were in the 
range of 18–48 % at 10 mmol L–1, indicating that their IC50 values could be higher than 10 
mmol L–1 (Table IV).
Anticancer activity
In vitro MTT assay. – New compounds showed cytotoxic activity against the three cell 
lines with IC50 values in the range of 0.08 to 3.92 µmol L–1, compared to lapatinib with IC50 
of 6.80–12.67 µmol L–1 (Table V). The 4-hydroxy derivatives 4a-c displayed IC50 values in the 
range of 0.08–3.79 µmol L–1 while the 4-chloro analogs 5a-c were slightly less active (IC50 = 
0.33–3.92 µmol L–1) against the three cell lines. Compounds 4c, 4b and 5b were the most 
active against the MCF-7, A2780 and HT29 cancer cell lines.
Structure activity relationship (SAR)
Compound 4a displayed IC50 values of 0.31, 2.56 and 0.96 µmol L–1 against MCF-7, 
A2780 and HT29 cells, resp. Substitution on ring A with the electron donating methyl 
group increased activity against the A2780 and HT29 cells, while the 4-chloro substitution 
increased activity against the MCF-7 and A2780 cancer cell lines. Moreover, replacement 
of 4-hydroxy in compound 4a with the chloro group (compound 5a) resulted in an increase 
in activity against the A2780 and HT29 cell lines (Fig. 4).
The anticancer activity of compounds 5a-c was dependent on the type of substituent 
on ring A. The 4-methyl substituent in compound 5b increased the activity against both 
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MCF-7 and A2780 cells, while the 4-chloro decreased the activity against the three cell 
lines. On the other hand, replacement of the 4-hydroxy group in compound 4b with the 
chloro group resulted in an increase of anticancer activity against both MCF-7 and A2780 
cells, while replacement of the 4-hydroxy group in compound 4c with the chloro group 
decreased the anticancer activity against both MCF-7 and A2780 cells.
In general, the electronic effect of various substituents on the anticancer activity varied 
with the cell line. Compound 4c with the electron withdrawing Cl-group displayed higher 
activity against the MCF-7 and A2780 cell lines than compounds 4a and 4b, while the 
methyl derivative 5b was more active than compounds 4a and 4c against these two cell 
lines. Accordingly, substituents on rings A and B of opposite electronic effects enhanced 
the anticancer activity against the MCF-7 and A2780 cell lines (Fig. 4).
Annexin V FITC/PI apoptosis assay
Annexin V propidium iodide(PI)/fluorescein isothiocyanate (FITC) apoptosis assay 
was used to evaluate the ability of the most active compound (5b) to induce apoptosis, fol-
lowing a previous report (26). The results are presented in Fig. 5. Compound 5b induced 
dose dependent early apoptosis C4 (early apoptosis): 10.6, 32.4, 33.6 and 41.7 %, resp., for 0, 
1, 5 and 10 µmol L–1. Only 0.1–0.2 % necrosis (C1) was induced in the MCF-7 cell population 
by compound 5b, following a 24-hour treatment. Compound 5b caused at least four-fold 
increase in the early apoptotic events.
Computational study
Drug-likeness study. – The results revealed that the new compounds 4a-c and 5a-c have 
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Fig. 4. SAR of the anticancer activity of the new compounds 4a-c and 5a-c.
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acceptor (HA) < 10, hydrogen bond donor (HD) ≤ 5, molar refractivity (MR) between 40 and 
130. Accordingly, all the new compounds have good drug-likeness scores in the range of 
0.55–1.00 compared to 0.58 for licofelone. No violation of Lipinski’s rule was observed for 
the new compounds, while licofelone showed one violation (see Table V).
Docking study
Due to the important role of COXs enzymes in inflammation, cell proliferation and 
apoptosis (4–7), a comparative docking study was performed to evaluate the binding 
modes and binding free energies of the new compounds into the active sites of COX-1/2.
Docking study into the active site of COX-1. – COX-1 (ovine) crystal structure complexed 
with ibuprofen (pdb code: 1EQG) (29) was obtained from the protein data bank (http://www.
rcsb.org/pdb/home/home.do). Validation of docking results was done by re-docking the native 
ligand (ibuprofen) into the active site of COX-1. A discovery studio visualizer (DSV) was used 
in visualization of the docking results. Docking results are presented in Table VII.
Results of the docking study revealed the ability of new compounds 4a-c and 5a-c to bind 
ARG120, TYR355, MET522 and SER530 amino acids in the active site of COX-1 with binding 
Fig. 5. Plots showing different phases of the staining of MCF-7 cells with annexin V FITC/PI, treated 
with compound 5b, for 24 h: a) control, 0 µmol L–1, b) 1 µmol L–1, c) 5 µmol L–1, d) 10 µmol L–1 (n = 3).
x-axis: annexin V, y-axis: propidium iodide (PI)
C1: (necrosis-death, PI+/annexin V-); C2: (late apoptosis, PI+/ annexin V+); C3: (living cells, PI-/an-
nexin V-); C4: (early apoptosis, PI-/annexin V+).
         a)                                                                              b)
        c)                                                                              d)
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5b –8.73 0.401 1 CH=N OH of TYR355 2.95



















4a –10.33 0.026 –e – – –
4b –10.88 0.011 –e – – –
4c –11.13 0.0069 –e – – –
5a –10.05 0.04265 1 CONH NH2 of ARG120 2.83
5b –10.59 0.01732 1 CONH NH2 of ARG120 2.89
5c –10.88 0.01061 1 CONH NH2 of ARG120 3.10












a COX-1 (pdb: 1eqg) (ref. 29) and COX-2 (pdb: 1cx2) (ref. 30).
b Binding free energy.
c Inhibition constant.
d HBs - hydrogen bonds.
e No hydrogen bond detected.
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free energy in the range of –7.71 to –9.12 kcal mol–1. Except for compound 4b, all the new com-
pounds showed binding affinity higher than ibuprofen (∆Gb = –7.85 kcal mol–1). In addition, all 
the new compounds formed 1–5 hydrogen bonds with the amino acids in COX-1 (Table VII and 
Fig. 6).
Docking into the active site of COX-2. – New compounds were also docked into the active 
site of COX-2 using AutoDock 4.2. The crystal structure of COX-2 (pdb code: 1CX2) (30) was 
Fig. 6. a) 3D docking mode of compound 4b into COX-1 (pdb code: 1EQG) showing four hydrogen 
bonds with ARG120, TYR355 and SER530 amino acids, b) 2D docking mode of compound 4b into 
COX-1 showing four hydrogen bonds, twelve hydrophobic interactions of the pi-sigma, alkyl and 
pi-alkyl types, c) 3D docking mode of compound 5b into COX-1 (pdb code: 1EQG) showing one hy-
drogen bond with TYR355, d) 2D docking mode of compound 5b into COX-1 showing one hydrogen 
bond and fifteen hydrophobic interactions of the pi-cation, pi-sigma, alkyl and pi-alkyl types.
         a)                                                                              b)
        c)                                                                               d)
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obtained from the protein data bank (http://www.rcsb.org/pdb/home/home.do). Validation 
of docking results was done through a re-docking scenario of the native ligand (SC-558) 
into the active site of the COX-2 enzyme. New compounds displayed binding affinities 
comparable to or slightly higher than the native ligand SC-558 (Table VII). Hydrophobic 
interaction was the main type of interaction between the new compounds and amino acids 
in the active site of the enzyme. Although compounds 5a-c showed only one hydrogen 
bonding with ARG120 in COX-2, their high binding affinities to COX-2 were mainly due to 
Fig. 7. a) 3D docking mode of compound 4b into COX-2 (pdb code: 1CX2), b) 2D docking mode of 
compound 4b into COX-2 showing eighteen hydrophobic interactions of the halogen (Cl), pi-cation, 
pi-sulfur, pi-sigma, amide-pi stacked, alkyl and pi-alkyl types, c) 3D docking mode of compound 5b 
into COX-2 (pdb code: 1CX2) showing one hydrogen bond with ARG120, d) 2D docking mode of 
compound 5b into COX-2 showing one hydrogen bond, nineteen hydrophobic interactions of the 
carbon-hydrogen, halogen (Cl), pi-sigma, amide-pi stacked, alkyl and pi-alkyl types.
         a)                                                                              b)
         c)                                                                              d)
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the formation of multiple hydrophobic interactions (Fig. 7). To sum up, compounds 4c and 
5c with the 4-chloro substitution on ring A displayed higher binding affinity to COX-2 than 
their methyl (4b and 5b) and unsubstituted analogs (4a and 5a).
CONCLUSIONS
A novel series of pyrrolizine-5-carboxamides derivatives 4a-c and 5a-c was prepared 
and evaluated for their anti-inflammatory, analgesic and anticancer activities. (EZ)-7-cya-
no-6-((4-hydroxybenzylidene)amino)-N-(p-tolyl)-2,3-dihydro-1H-pyrrolizine-5-carboxamide 
(4b) and (EZ)-6-((4-chlorobenzylidene)-amino)-7-cyano-N-(p-tolyl)-2,3-dihydro-1H-pyrroli-
zine-5-carbox-amide (5b) bearing the electron donating methyl group showed the highest 
anti-inflammatory activity 3 hours after induction of inflammation, while (EZ)-7-cyano-
6-((4-hydroxybenzylidene)amino)-N-phenyl-2,3-dihydro-1H-pyrrolizine-5-carboxamide (4a) 
and (EZ)-6-((4-chlorobenzylidene)amino)-7-cyano-N-phenyl-2,3-dihydro-1H-pyrrolizine-
5-carboxamide (5a) were the most active analgesic agents.
Cytotoxicity of the new compounds was evaluated against the MCF-7, A2780 and HT29 
cancer cell lines where the results revealed high anticancer activity. Substituents with op-
posite electronic effects on the two phenyl rings enhanced the anticancer activity against the 
MCF-7 and A2780 cell lines. (EZ)-N-(4-chlorophenyl)-7-cyano-6-((4-hydroxybenzylidene)-
amino)-2,3-dihydro-1H-pyrrolizine-5-carboxamide (4c) displayed the highest anticancer 
activity against the MCF-7 and A2780 cell lines with IC50 values of 0.08 and 0.52 µmol L–1, 
resp. COX inhibition was suggested as the possible mechanism of action of the anti-inflam-
matory activity of the new compounds. Results of the COX-1/2 inhibition assay showed ap-
preciable inhibitory activity with higher inhibitory activity of COX-2. Although compound 
4c with the highest inhibition of COX-2 displayed the highest anticancer activity against the 
MCF-7 and A2780 cell lines, it was the least active against COX-2 producing HT29 cells. In 
addition, compound 5b which displayed the lowest inhibition of COX-2 was the most active 
against the three cancer cell lines. These findings suggest that targets other than COX en-
zymes mediate the anticancer activity of these compounds. Annexin V PI/FITC apoptosis 
assay revealed the ability of compound 5b to induce dose-dependent early apoptosis with 
0.1–0.2 % necrosis in MCF-7 cells.
The drug-likeness study showed promising bioactivity scores for the new compounds. 
The docking study of the new compounds into COX-1/2 revealed high binding affinities 
for COX-2. Taken together, this study has confirmed the significant impact of different 
substituents on the biological activity of pyrrolizine-5-carboxamides, which could help in 
further optimization to discover good leads for the treatment of cancer and inflammation.
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